{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:18Z","timestamp":1788250458306,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Metastatic squamous cell carcinomas (SCC) of the anal canal are rare and there is no international consensus on their second\u2010line management. 5\u2010Fluorouracil (5\u2010FU) and mitomycin in combination with radiotherapy is the standard for locally advanced forms but its efficacy in metastatic stage has never been evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We report a retrospective analysis of patients treated with 5\u2010FU and mitomycin from 2000 to 2017 in our institution for a metastatic SCC of the anal canal after failure of platinum\u2010based regimen. The main outcome was progression\u2010free survival (PFS) and the secondary outcomes were overall survival (OS), response rate, and toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nineteen patients, 15 women and four men, with a median age of 57\u00a0years were identified (range, 40\u201079\u00a0years). Patients received a median of three cycles (1\u20107) of mitomycin 5\u2010FU. A dose reduction was necessary in six patients (31.6%), one patient had to discontinue treatment following toxicity and no death was due to treatment toxicity was reported. An objective response was observed in five patients (26.4%, 95% CI 6.6\u201046.2) including one complete response, six patients (31.6%, 95% CI 10.7\u201052.5) showed tumor stabilization. Median PFS and OS were 3\u00a0months [95% CI 1\u20105] and 7\u00a0months [95% CI 2.2\u201011.8]. Responder had a median duration of response of 4\u00a0months [95% CI 1.8\u20106.1] and one patient had 23\u00a0months duration of response. No significant difference was noted for PFS and OS for patients previously treated with mitomycin and 5\u2010FU at a local stage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Mitomycin and 5\u2010FU regimen provides tumor control with acceptable tolerance. It is an option for patients with metastatic SCC of the anal canal after failure of platinum\u2010based chemotherapy. [Correction added on 9 October 2019, after first online publication: '5\u2010FU' was inadvertently removed from the Results and Conclusion and has now been added to the text.]<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.2558","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T11:53:06Z","timestamp":1568634786000},"page":"6853-6859","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mitomycin and 5\u2010fluorouracil for second\u2010line treatment of metastatic squamous cell carcinomas of the anal canal"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3183-1611","authenticated-orcid":false,"given":"Ang\u00e9lique","family":"Saint","sequence":"first","affiliation":[{"name":"Digestive Oncology Department of Medical Oncology Centre Antoine Lacassagne Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Evesque","sequence":"additional","affiliation":[{"name":"Digestive Oncology Department of Medical Oncology Centre Antoine Lacassagne Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Falk","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Centre Antoine\u2010Lacassagne Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Cavaglione","sequence":"additional","affiliation":[{"name":"Digestive Oncology Department of Medical Oncology Centre Antoine Lacassagne Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Montagne","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Centre Antoine\u2010Lacassagne Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Benezery","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Centre Antoine\u2010Lacassagne Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Francois","sequence":"additional","affiliation":[{"name":"Digestive Oncology Department of Medical Oncology Centre Antoine Lacassagne Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70137-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.12.052"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900600815208"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8085"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80702-8"},{"issue":"10","key":"e_1_2_9_7_1","first-page":"861","article-title":"5\u2010fluorouracile and cisplatinum combination chemotherapy for metastatic squamous\u2010cell anal cancer","volume":"86","author":"Faivre C","year":"1999","journal-title":"Bull Cancer"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0698-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000000827"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30321-8"},{"key":"e_1_2_9_11_1","unstructured":"Carboplatin Plus Paclitaxel Respresents a New Standard of Care for Patients with Squamous Cell Carcinoma of the Anal Canal. ESMO.https:\/\/www.esmo.org\/Oncology-News\/InterAACT-inoperable-locally-recurrent-metastatic-anal-cancer-Rao. Accessed October 24 2018."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0060"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx029"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.04.013"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000363"},{"issue":"4","key":"e_1_2_9_17_1","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts","volume":"4","author":"Sawada N","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"2","key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02988857","article-title":"5\u2010Flugrouracil (FU) and mitomycin c (MMC) in the management of colorectal carcinoma. Part II.in vitro activity of the two drugs in short term tumor cultures","volume":"8","author":"Franchi F","year":"1991","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2527"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1914"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2013.01.005"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.11.006"},{"issue":"12","key":"e_1_2_9_24_1","first-page":"4637","article-title":"Single\u2010agent paclitaxel in advanced anal cancer after failure of cisplatin and 5\u2010fluorouracil chemotherapy","volume":"31","author":"Abbas A","year":"2011","journal-title":"Anticancer Res"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000361051"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0241"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000383"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000452766"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4051"},{"key":"e_1_2_9_30_1","unstructured":"Cetuximab + Avelumab or Avelumab Alone for Unresectable Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03944252. Accessed May 9 2019."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2010.01334.x"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0963-2"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1179\/1973947812Y.0000000021"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2558","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T15:01:34Z","timestamp":1710255694000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":32,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/cam4.2558"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2558","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"2019-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}